Article
KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.
International journal of molecular sciences - 20 May 2021
Jaromi Luca, Csongei Veronika, Vesel Monika, Abdelwahab ElHusseiny Mohamed Mahmud, Soltani Amina, Torok Zsofia, Smuk Gabor, Sarosi Veronika, Pongracz Judit Erzsebet
Abstract excerpt
Lung carcinoma is still the most common malignancy worldwide. One of the major subtypes of non-small cell lung cancer (NSCLC) is adenocarcinoma (AC). As driver mutations and hence therapies differ in AC subtypes, we theorized that the expression and function of ABC drug transporters important in multidrug resistance (MDR) would correlate with characteristic driver mutations KRAS or EGFR. Cisplatin resistance (CR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.